Phages for Animal Nutrition Market Report: The 43% CAGR Precision Microbiome Technology Disrupting Global Antibiotic-Free Production The livestock industry is confronting a moment of reckoning. By 2025, over 100 countries have implemented regulatory restrictions on antibiotic growth promoters (AGPs), yet the biological demands of intensive production remain unchanged: producers must control enteric pathogens, maintain feed conversion efficiency, and prevent post-weaning mortality without the prophylactic tools that defined the previous half-century of animal agriculture . Conventional alternatives—organic acids, phytogenics, probiotics—have proven partial solutions at best, often delivering inconsistent field results that erode return on investment. Enter bacteriophages for animal nutrition: nature's most abundant biological entities, repurposed as precision-targeted gut health interventions that kill specific pathogens while leaving beneficial microbiota intact. According to QYResearch's latest comprehensive analysis, this technology is poised to transform from a niche scientific curiosity into a mainstream feed additive category, with the global market projected to surge from USD 98 million in 2025 to USD 1.16 billion by 2032, expanding at an extraordinary CAGR of 43.0%. Global Leading Market Research Publisher QYResearch announces the release of its latest report “Phages for Animal Nutrition - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Phages for Animal Nutrition market, including market size, share, demand, industry development status, and forecasts for the next few years. The global market for Phages for Animal Nutrition was estimated to be worth USD 98 million in 2025 and is projected to reach USD 1,156 million, growing at a CAGR of 43.0% from 2026 to 2032. 【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】 https://www.qyresearch.com/reports/6082037/phages-for-animal-nutrition The Science Driving the Surge: Why Phages, Why Now For the CEO or investor evaluating this space, the core value proposition rests on a fundamental biological distinction. Phages are viruses that solely kill and selectively target bacteria. They are the most common biological entities in nature and have been shown to effectively fight and destroy multi-drug resistant bacteria. Namely, when all antibiotics fail, phages still succeed in killing the bacteria and may save a life from an infection. Phage has many potential applications in human medicine as well as dentistry, veterinary science, and agriculture. Bacteriophage settles in the animal intestine and controls the population balance of gut microflora by reducing the number of specific pathogenic microorganisms, promoting animal growth, and improving feed efficiency. This mechanism of action addresses the central weakness of broad-spectrum antibiotics: collateral damage to beneficial gut microbiota. Unlike traditional AGPs that suppress both pathogenic and commensal bacteria indiscriminately, phage-based feed additives exhibit strain-level specificity—eliminating Salmonella enteritidis, Clostridium perfringens, or pathogenic Escherichia coli while preserving the Lactobacillus and Bifidobacterium populations critical to immune development and nutrient absorption. This precision translates into measurable performance outcomes. Commercial trials in broiler production conducted across Southeast Asia in 2024 demonstrated that phage-supplemented diets targeting Salmonella and Clostridium achieved equivalent or superior feed conversion ratios compared to antibiotic-treated controls, while reducing pathogen colonization below detection thresholds—a dual benefit of productivity enhancement and food safety improvement that resonates powerfully with vertically integrated poultry processors. Market Size Trajectory: From Niche to Mainstream The growth curve from USD 98 million to USD 1.16 billion at a 43.0% CAGR represents one of the most aggressive expansion trajectories within the broader animal nutrition sector, substantially outpacing probiotics (approximately 8-9% CAGR) and phytogenic feed additives (approximately 7-8% CAGR). This exponential growth pattern is characteristic of transformative technologies transitioning from early adoption to mainstream integration, driven by a confluence of regulatory catalysis and manufacturing maturation. The regulatory landscape has shifted decisively in favor of phage-based solutions. In January 2026, the European Food Safety Authority (EFSA) published its updated Qualified Presumption of Safety (QPS) list, which for the first time declared bacteriophages eligible for QPS status at the species level—a landmark regulatory milestone that fundamentally alters the commercialization pathway for phage products in the European Union . The QPS designation enables a streamlined, fast-tracked safety assessment process for phage feed additives, reducing dossier preparation timelines and regulatory uncertainty that had previously constrained investment in the sector. This development, combined with the existing U.S. FDA Generally Recognized as Safe (GRAS) determinations for several phage preparations targeting Listeria and Salmonella in food applications, creates a transatlantic regulatory framework conducive to market expansion. Concurrently, manufacturing capabilities are scaling rapidly. In September 2025, the Canadian government's National Research Council awarded a significant contribution agreement to Cytophage Technologies Inc. specifically addressing "Production and Quality Challenges in Commercializing Phage Biologics for Animal Health" . This publicly funded initiative aims to enable GMP-certified manufacturing of phage-based animal health products, targeting the production bottlenecks that have historically constrained commercial scalability—notably the challenges of maintaining phage viability during spray-drying, achieving homogeneous distribution in feed matrices, and establishing stability throughout the product shelf life. The commercialization of large-scale phage fermentation and formulation technologies is expected to reduce production costs by 40-60% over the forecast period, accelerating adoption beyond early-adopter premium segments into mainstream poultry, swine, and aquaculture operations. Competitive Landscape: The Race for Market Positioning The competitive structure of the phages for animal nutrition market remains fluid, characteristic of an early-stage industry where technological capabilities and regulatory approvals, rather than installed manufacturing capacity, determine competitive positioning. Key industry participants identified in the QYResearch report include Phagelux AgriHealth, Shandong Sinder Technology, Qingdao Noan Baite Biotechnology, Green Long Biotech, Qingdao RunDa Biotechnology, Shandong New Line Biotechnology, Nongbo Mushroom Society Biotechnology, NPO Microgen, Proteon Pharmaceuticals, Phagelux, and PhageLab. Notable patterns emerge from the competitive landscape. Chinese biotechnology firms—including Shandong Sinder Technology, Qingdao Noan Baite Biotechnology, and Green Long Biotech—collectively represent a substantial and growing share of global phage production capacity, reflecting China's strategic prioritization of antibiotic alternatives following its comprehensive 2020 AGP ban and the government's subsequent five-year agricultural biotechnology initiatives. These manufacturers have leveraged domestic bacteriophage strain libraries accumulated through decades of research at provincial agricultural universities to develop multi-phage cocktails targeting the specific enteric pathogen profiles prevalent in Asian swine and poultry production systems. European and North American players, including Proteon Pharmaceuticals and Cytophage Technologies, are pursuing differentiated strategies emphasizing regulatory sophistication and manufacturing quality assurance as competitive moats. A comprehensive review published in March 2026 identified convergent technical requirements across major regulatory jurisdictions—including genomic integrity verification confirming the absence of toxin-encoding and antimicrobial resistance genes, purity specifications exceeding 99% phage particles, and matrix-validated efficacy data—that favor manufacturers with established quality management systems and regulatory affairs capabilities . Product Segmentation: Formulation Formats and Application-Specific Solutions The market segments by product type into Powder and Preparation formats, with each serving distinct channel requirements and end-user preferences. Powder formulations—typically produced via spray-drying with protective encapsulants such as trehalose or maltodextrin to maintain phage viability during thermal processing—dominate the feed mill integration channel, where compatibility with existing micro-ingredient addition systems and finished feed stability over 3-6 month shelf lives are non-negotiable requirements. Preparation formats, encompassing liquid suspension concentrates for drinking water application and gel-based delivery systems for hatchery or farrowing room administration, offer greater dosing flexibility and are preferred in production systems where real-time pathogen monitoring informs dynamic treatment protocols. The application landscape covers Ruminants, Poultry, Aquaculture, and other specialty segments. Poultry—encompassing broilers, layers, and breeders—represents the largest current application segment, driven by the acute economic impact of necrotic enteritis caused by Clostridium perfringens, estimated to cost the global poultry industry in excess of USD 6 billion annually in lost productivity and mortality. Phage-based interventions specifically targeting toxigenic C. perfringens strains have demonstrated mortality reduction of 40-60% in challenge studies, positioning this application as the gateway segment for broad commercial adoption. Aquaculture represents the highest-growth vertical within the forecast period, with phage products targeting Vibrio parahaemolyticus in shrimp and Yersinia ruckeri in salmonids addressing production diseases for which effective, regulatory-compliant interventions remain scarce . Regulatory Harmonization: The Critical Growth Catalyst The single most important variable determining the trajectory of the phage for animal nutrition market through 2032 is the pace and extent of international regulatory harmonization. A comprehensive review published in August 2025 by the International Alliance for Biological Standardization (IABS) concluded that the current regulatory environment is "not conducive to the development of phage products and is considered to act as a barrier in many cases" . The core challenge identified is the classification ambiguity facing phage products—which can be regulated as veterinary medicinal products, feed additives, magistral preparations, or biocides depending on jurisdiction and intended use, each pathway imposing distinct manufacturing, safety, and efficacy demonstration requirements that were not originally designed for biological products . The EFSA QPS update of January 2026 represents the most significant regulatory advancement toward harmonization, establishing a scientifically rigorous, internationally recognized safety assessment framework that other regulatory agencies may adopt or reference . For the corporate strategist evaluating market entry timing, the implication is clear: the 2026-2028 window represents the optimal period for securing regulatory approvals and establishing brand positioning before the market transitions from early-adopter dynamics to competitive intensity as harmonization enables broader participation. Subsequent chapters of this report provide granular regional market breakdowns, pricing analysis across powder and preparation segments, and comprehensive competitive profiling of the leading manufacturers through 2032. Contact Us: If you have any queries regarding this report or if you would like further information, please contact us: QY Research Inc. Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States EN: https://www.qyresearch.com E-mail: global@qyresearch.com Tel: 001-626-842-1666 (US) JP: https://www.qyresearch.co.jp